NCT00574275 - Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

546

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2010

Conditions

Pancreatic Neoplasm

Interventions

DRUG

Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.

DRUG

Placebo

4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle

DRUG

Gemcitabine

1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.

Trial Locations (24)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Sofia

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Nicosia

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Athens

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, San Juan

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Brastislava

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Geneva